UBI to cut stake in Shanghai Shen Lian Biomedical

UNITED BIOMEDICAL, INC. (UBI), a major shareholder in Shanghai Shen Lian Biomedical Corporation, plans to reduce its stake by up to 3% of the company's total shares. This reduction, totaling up to 12,319,320 shares, will occur between November 13, 2025, and February 12, 2026. UBI currently holds 10.52% of the company's shares, amounting to 43,199,898 shares, acquired before the company's initial public offering.

The reduction will be executed through both centralized bidding and block trading. Up to 4,106,440 shares will be sold via centralized bidding, and up to 8,212,880 shares through block trading. The proceeds from this sale are intended to fund clinical trials, commercialization, and the development of manufacturing bases for UBI's innovative drug pipeline, including an Alzheimer's synthetic peptide vaccine.

This planned share reduction will not alter Shanghai Shen Lian Biomedical Corporation's control, as UBI is not the largest shareholder, controlling shareholder, or actual controller. The transaction will adhere to market prices, not falling below the initial public offering price, and complies with relevant regulatory requirements.